# Starling Oncology, Inc. Common Stock (STLN)

> Starling Oncology, Inc. Common Stock (STLN) trades at $3.50 (-6.67%) as of 7:58:50 PM EST on Nov 13, 2026, -49.35% over the past month. Market cap is $382.47M, with 5.4 days to cover in short interest.

Canonical: https://massive.com/quote/stln
Data as of: 2026-11-14T00:58:50.241Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$3.50** -0.25 (-6.67%)
As of 7:58:50 PM EST on Nov 13, 2026 · 15-minute delayed
Nasdaq · usd

## Stock performance

How Starling Oncology, Inc. Common Stock (STLN) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | -6.67% |
| 1W | -3.31% |
| 1M | -49.35% |
| YTD | -32.30% |
| 1Y | -32.30% |
| 52-wk range | $3.30 – $7.13 |

From daily closes through Nov 13, 2026.

## Key statistics

Today's trading snapshot for STLN: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $3.30 – $3.78 |
| Open | $3.76 |
| Prev close | $3.75 |
| Volume | 23.02M |
| Market cap | $382.47M |
| Shares out | 99.98M |

## Valuation and profitability ratios

Valuation and profitability ratios for Starling Oncology, Inc. Common Stock: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | — |
| P/S | 0.62 |
| P/B | -10.24 |
| P/FCF | 20.31 |
| ROE | 92.2% |
| ROA | -18.4% |
| Debt/Equity | -2.08 |
| Div yield | 0.00% |

As of Nov 12, 2026

## Insider trading

[Starling Oncology, Inc. Common Stock (STLN) insider trading](https://massive.com/quote/stln/insider-trading.md): open-market Form 4 buys and sells by Starling Oncology, Inc. Common Stock insiders over the last 12 months.

## 8-K filings

Material corporate events Starling Oncology, Inc. Common Stock has disclosed to the SEC on Form 8-K.

- Nov 12, 2026 · Investor presentation
  “Starling Oncology, Inc. (the "Company") has prepared an investor presentation (the "Investor Presentation") to use in meetings with investors. A copy of the Investor Presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K.”
- Nov 5, 2026 · [Quarterly earnings](https://massive.com/quote/sec-filings/8-k/earnings-releases.md)
  “On November 5, 2026, Starling Oncology, Inc. (the "Company") issued a press release announcing its financial results for the three months ended September 30, 2026 and certain other financial information.”
- Sep 2, 2026 · Director departure
  “On September 1, 2026, Brad Hively notified Starling Oncology, Inc. (the "Company") of his decision to not stand for re-election to the Board of the Directors of the Company (the "Board") at its 2027 annual meeting of stockholders (the "Annual Meeting"). Mr. Hively is expected to continue to serve as a director of the Company until the Annual Meeting, but effective immediately, will no longer serve as Vice Chairman of the Board or as a member of the Compliance Committee or any other committees of the Board.”
- Aug 21, 2026 · Credit facility
  “On August 20, 2026, Starling Oncology Management, Limited Liability Company entered into a Credit Agreement (the 'Revolving Loan Agreement') among SOM, LLC and Gemino Healthcare Finance, LLC d/b/a SLR Healthcare ABL, as lender. The Revolving Loan Agreement provides access to a revolving line of credit facility in the aggregate principal amount of up to $25 million (the 'Revolving Loan Commitment').”

## STLN short interest

How heavily STLN is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 5.4 |
| Short interest | 6.84M |
| Avg volume | 1.26M |

As of Oct 30, 2026 · reported to FINRA twice monthly.

## STLN news

The latest news and headlines about Starling Oncology, Inc. Common Stock (STLN).

- [Starling Oncology, Inc. (STLN) Reports Q3 Loss, Beats Revenue Estimates](https://www.zacks.com/stock/news/3024900/starling-oncology-inc-stln-reports-q3-loss-beats-revenue-estimates?cid=CS-ZC-FT-fundamental_analysis|yseop_template_4-3024900) · Zacks Investment Research · Nov 5, 2026 · negative sentiment
- [Ultragenyx (RARE) Reports Q3 Loss, Lags Revenue Estimates](https://www.zacks.com/stock/news/3022232/ultragenyx-rare-reports-q3-loss-lags-revenue-estimates?cid=CS-ZC-FT-fundamental_analysis|yseop_template_4-3022232) · Zacks Investment Research · Nov 3, 2026 · neutral sentiment

## About Starling Oncology, Inc. Common Stock

Starling Oncology Inc provides oncology care services in community settings. Its services include cancer diagnosis and treatment, clinical trials, transfusion services, and other oncology care delivery models for patients.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE |
| Employees | 641 |
| Listed | Nov 15, 2021 |

[Company website](https://www.starlingoncology.com)

## FAQ

### What is the Starling Oncology, Inc. Common Stock (STLN) stock price today?

Starling Oncology, Inc. Common Stock (STLN) is trading at $3.50 (-6.67% on the day) as of 7:58:50 PM EST on Nov 13, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is Starling Oncology, Inc. Common Stock?

Starling Oncology Inc provides oncology care services in community settings. Its services include cancer diagnosis and treatment, clinical trials, transfusion services, and other oncology care delivery models for patients.

### What is the short interest in STLN?

As of Oct 30, 2026, STLN has 6.84M shares short and 5.4 days to cover.

### What exchange is STLN listed on?

Starling Oncology, Inc. Common Stock (STLN) trades on Nasdaq in USD, in the SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE industry.

## Live data

Prices here are 15-minute delayed. For real-time STLN quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=STLN`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Starling Oncology, Inc. Common Stock (STLN) insider trading](https://massive.com/quote/stln/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms
